tbuckley/cabot-search huggingface dataset:
AB0163 Inhibition of Lymphocyte Activation in Primary SjÖgren Syndrome (PSS)
Authors: A. Balog, N. Legány, N. Megyes, G. Toldi
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> Primary Sjögren9s syndrome (pSS) is an autoimmune diseases characterized by ocular and oral dryness due to the progressive destruction of lachrymal and salivary glands by an inflammatory process. The short-term activation of peripheral blood and exocrin glands T lymphocytes plays a crucial role in initiating and maintaining the chronic inflammation. The transient increase of the cytoplasmic free calcium level plays a key role in the process of lymphocyte activation. Kv1.3 and IKCa1 potassium channels are important regulators of the maintenance of calcium influx during lymphocyte activation. The influx of calcium is maintained by the function of potassium channels that conserve the electrochemical potential gradient via the efflux of potassium from the cytoplasm. Recent reports raised the notion that the inhibition of lymphocyte potassium channels, especially that of the Kv1.3 channel would be an optimal solution for specific immunosuppression in autoimmune disorders. Therefore, in this study we aimed to characterize the effects of lymphocyte potassium channel inhibition on short-term peripheral blood T lymphocyte activation in major lymphocyte subsets in pSS. <h3>Methods</h3> We enrolled 8 healthy individuals and 15 pSS patients. We evaluated calcium influx kinetics following activation in CD4, Th1, Th2 and CD8 cells applying a novel flow cytometry approach. We assessed the sensitivity of the above subsets to specific inhibition of the Kv1.3 and IKCa1 potassium channels. We also assessed the Kv1.3 expression on lymphocytes. <h3>Results</h3> The peak of calcium influx in lymphocytes isolated from pSS patients is reached later, indicating that they respond more slowly to stimulation compared to controls. In healthy individuals, the inhibition of the IKCa1 channel decreased calcium influx in Th2 and CD4 cells to a lower extent than in Th1 and CD8 cells. On the contrary, the inhibition of Kv1.3 channels resulted in a larger decrease of calcium entry in Th2 and CD4 than in Th1 and CD8 cells. Neither the inhibition of IKCa1 channel nor the inhibition of Kv1.3 channels has an influence on intracellular calcium kinetic in pSS. The expression of Kv1.3 channels on CD4, Th2 and CD8 lymphocytes was significantly higher compared to controls. <h3>Conclusions</h3> There is an alteration of the short-term activation of peripheral lymphocytes in pSS. The inhibition of Kv1.3 and IKCa1 channels does not seem to be specific enough in peripheral pSS lymphocytes. The overexpression of Kv1.3 channels in pSS might be a compensatory mechanism of the dysfunction of Kv1.3 and IKCa1 channels, theoretically. <h3>Disclosure of Interest</h3> None declared
Aviation Medicine.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study—GETHI 2013-01.
Authors: Jf. Rodriguez-Moreno, Jesús García-Donas, Laia Garrigos, Nuria Laínez, Ana Santaballa, Andrés Redondo, Juan Fernando Cueva, Maria Jesus Rubio, Susana Hernando Polo, Isabel Bover, Isabel Palacio, Zaida Garcia-Casado, Enrique Grande, Alicia Hurtado
Journal: Journal of Clinical Oncology (2015)

TPS5612 Background: Granulosa-cell tumors (GCT) of the ovary are a rare entity characterized by presenting a punctual mutation at the FOXL2 gene 402C→G (C134W) in most cases. Such mutation is responsible for a disregulation and overstimulation of the steroidogenic pathway, that ultimately leads to hormone overproduction. A prior trial by our group (GREKO I trial-GETHI 2011-03; NCT01584297) showed promising activity of ketoconazole, a CYP17 inhibitor used to control steroidogenesis in several conditions. Thus, we aim to assess the activity of Orteronel (TAK700), a selective inhibitor of 17, 20-lyase, in GCT. Methods: An open-label phase II single arm clinical trial has been designed for women with metastatic or locally advanced non-resectable granulosa cell ovarian tumor that harbors the somatic mutation FOXL2 402C→G (C134W) and who have not received prior treatment with any CYP17 inhibitor. Treatment will consist on Orteronel 300mg BID, given orally, continuously in a 28-day treatment cycle. The primary objective is clinical benefit rate; secondary objectives are response rate, progression free and overall survival, assessment of the impact of Orteronel in reducing hormonal overproduction and toxicity. Sample size calculation is based on a a two stage Simon´s design that will lead to enroll 12 evaluable participants in stage one and 4 participants in stage two if one or more participants achieved a CR, PR or stable disease longer than 6 months. 16 subjects will allow a 80% power to differentiate between a 5% and a 25% clinical benefit rate. Probability of early termination of the trial is .54. 20% of losses have been assumed thus 20 patients will be enrolled in 9 spanish institutions (members of hte Spanish Group for Research in Orphan and Unfrequent Tumors-GETHI). Key inclusion criteria are histological diagnosis of GCT, advanced disease (meseaurable or evaluable by RECIST), availability of biopsy material for centralized pathologist review and assessment of the FOXL2 mutation. Key exclision criteria is prior therapy with orteronel, ketoconazole, abiraterone, aminoglutethimide or enzalutamide. Two patients have already been included. Clinical trial information: NCT02101684.
MEDICINE AND LETTERS.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Penance
Authors: Jordan D. Grumet
Journal: Annals of Internal Medicine (2009)

Ad Libitum20 January 2009PenanceJordan D. Grumet, MDJordan D. Grumet, MDFrom Evanston, IL 60201.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-2-200901200-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I'e startedTo bleedAgainIt happensEvery winterWith coldAnd dryI wash my hands20-30 × a dayBefore and afterEachPatientAt firstThe drynessWas bothersomeAnd I usedLotionBut eventuallyI stoppedAnd my handsBecame painfulBut the painGraduallyDisappearedOccasionallyBloodOn my knuckleWhere the skinWould crackThe other dayI was callingResultsA normal stress testA high cholesterolAnd lastlyI cameTo yourBiopsyQuietlyI told youOver the phoneYou criedCalmlyI explainedWhat happensNextAs I hung upI noticedI was wringingMy handsTogetherI looked downWith alarmTo seeI was coveredIn bloodThe cuffsOf my white coatStainedRedI ranTo the sinkMy tearsJoining the waterDownThe drainI guessI have been hurtingFor a veryLong timeHoweverSometimesI forgetTo thinkAboutItJordan ... Author, Article, and Disclosure InformationAffiliations: From Evanston, IL 60201.Current Author Address: Jordan D. Grumet, MD, 2321 Bryant Avenue, Evanston, IL 60201. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 January 2009Volume 150, Issue 2Page: 152KeywordsBiopsyHematologic testsHypercholesterolemiaInterleukins ePublished: 20 January 2009 Issue Published: 20 January 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Procedural results and late clinical outcomes in patients with low left ventricular ejection fraction undergoing stent implantation in saphenous vein grafts Javed M. Ahmed, Augusto D. Pichard, Lowell F. Satler, Gary S. Mintz, Luis Gruberg Hongsheng Wu, John R. Laird, Kenneth M. Kent, Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
BASEM Congress 2000
Authors: S Davies, M Coetsee, J Hussey, J Gormley
Journal: British Journal of Sports Medicine (2002)

Methods: Parameters measured included stature, mass, percentage body fat, maximal oxygen uptake (VO 2 MAX), maximal heart rate, and lactate after a treadmill run.All subjects freely volunteered after completing an informed consent form.Results: The results indicate that elite SA beach volleyball players are generally shorter 185.28 cm and lighter 82.01 kg than elite indoor players, and a higher in percentage body fat 13.12%.Their physiological characteristics indicated a mean VO 2 MAX of 59.37 ml/kg/min with a maximal heart rate of 189.38 bpm and lactate measure of 11.87 mmol/L after a treadmill run to exhaustion.Conclusions: The results suggest that a lack of emphasis on positional specialisation in beach volleyball appears to have mitigated against the extreme physiques often observed in indoor volleyball players.Interestingly it would seem elite beach volleyball players have superior selected physiological characteristics in terms of VO 2 MAX and lactate measures after a maximal treadmill run to exhaustion when compared to indoor players.This would imply that training and playing on sand may have beneficial physiological outcomes when compared to doing similar activities on a hard non-compliant terrain (assuming that there are no major genetic differences between performers).
TERT PROMOTER METHYLATION AS A POTENTIAL PROGNOSTIC BIOMARKER FOR PROGRESSION OF UNEXPLAINED CYTOPENIA TO MDS AND AML
Authors: K. Kaastrup, L. Gillberg, D. Aslan, L. S. Kristensen, A. D. Ørskov, J. W. Hansen, K. Grønbæk
Journal: HemaSphere (2019)
Angina Pectoris
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Campylobacter Enterocolitis
Authors: J. R. LAMBERT
Journal: Annals of Internal Medicine (1979)

Letters and Corrections1 December 1979Campylobacter EnterocolitisJ. R. LAMBERT, M.B., B.S., M. A. KARMALI, M.B. CH.B., A. NEWMAN, M.D.J. R. LAMBERT, M.B., B.S.Search for more papers by this author, M. A. KARMALI, M.B. CH.B.Search for more papers by this author, A. NEWMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-91-6-929_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The importance of campylobacter enteritis as a diarrheal illness has been underscored by Blaser and colleagues (1) in the August 1979 issue. During the past year we have seen 16 adult patients with proven Campylobacter fetus subspecies (ssp.) jejuni enteritis, and we would like to offer some additional comments about this illness.The clinical features of our cases in Toronto, some of which have been previously reported (2), are identical to those in the Denver study. We have been struck by the frequency with which blood and pus appear in the stool rather late in the course...References1. BLASERBERKOWITZLAFORCECRAVENSRELLERWANG MIMJLW. Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med. 1979;91:179-85. LinkGoogle Scholar2. LAMBERTTISCHLERNEWMAN JMA. Campylobacter enteritis: frequency in hospitalized patients and site of infection. Gastroenterology. 1979;76:1179. Abstract. Google Scholar3. LAMBERTTISCHLERKARMALINEWMAN JMMA. Campylobacter ileocolitis: an inflammatory bowel disease. Can Med Assoc J. In press. Google Scholar4. LINDEMANWEINSTEINLEVITANPATTERSON RLRJ. Ulcerative colitis and intestinal salmonellosis. Am J Med Sci. 1967;254:855-61. CrossrefMedlineGoogle Scholar5. LAMBERTSCHOFIELDIRONSIDEMANDAL MPAB. Campylobacter colitis. Br Med J. 1979;1:857-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Mount Sinai Hospital and the Hospital for Sick Children University of Toronto Ontario Canada, M5G IX5 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByOccurrence of Clostridium difficile Toxin in Inflammatory Bowel DiseaseIntestinal colonization of neonatal animals by Campylobacter fetus subsp. jejuniAssociation of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel diseaseCAMPYLOBACTER JEJUNI CAUSING FLARE-UP IN INFLAMMATORY BOWEL DISEASEPOTASSIUM CHLORIDE AND THROMBOEMBOLIC COMPLICATIONS: A HYPOTHESISThe gay bowel syndrome: A common problem of homosexual patients in the emergency department 1 December 1979Volume 91, Issue 6Page: 929-930KeywordsBloodCampylobacterDiarrheaEnteritisEnterocolitisFetuses Issue Published: 1 December 1979 PDF DownloadLoading ...
Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort
Authors: Tongai Gibson Maponga, Anna Mcnaughton, Marije Van Schalkwyk, Susan Hugo, Chikezie Nwankwo, Jantjie Taljaard, Jolynne Mokaya, David Smith, Cloete Jansen van Vuuren, Dominique Goedhals, Shiraaz Gabriel, Monique Andersson, Wolfgang Preiser, Christo van Rensburg, Philippa Matthews
Journal: Journal of Hepatology (2020)
Late onset bowel dysfunction after pelvic radiotherapy: a national survey of current practice and opinions of clinical oncologists
Authors: C. Henson, J. Andreyev, P. Symonds, D. Peel, R. Swindell, S. Davidson
Journal: Gut (2011)

<h3>Introduction</h3> 17,000 patients receive treatment with radical pelvic radiotherapy annually in the UK. Up to 50% of patients will develop bowel symptoms which affect quality of life. Services for this patient group are underdeveloped. Barriers to good clinical care include poor patient reporting, poor clinician recognition and a lack of established routes of referral. The National Cancer Survivorship Initiative (2007) has identified access to specialist medical care for those with complications that occur after cancer as one of the four key needs of cancer survivors. It is in this context that we aimed to determine the current practice of clinical oncologists in the UK. <h3>Methods</h3> A questionnaire was developed and sent to the 314 clinical oncologists in the UK who treat pelvic malignancies up to a maximum of three times by post. <h3>Results</h3> 190 (61%) responses were received. 76% of oncologists screen for GI dysfunction after pelvic radiotherapy. 85% screen for symptoms through history taking with only 11% using formal screening questionnaires. Clinical oncologists view toxicity as a significant problem, with 64% estimating that up to 24% patients have bowel symptoms at 1 year. 71% oncologists refer &lt;50% of their symptomatic patients, with 48% referring &lt;10%. These referrals are sent to a gastroenterologist from 31% of oncologists and to a GI surgeon from 23%, with 33% referring to either speciality. 58% do not have access to a gastroenterologist or GI surgeon with a specialist interest in their area. 65% of oncologists think a service is required specifically for patients with bowel dysfunction after pelvic radiotherapy, but 52% rate the current service in their area as inadequate. Oncologists state an ideal service would be gastroenterology-lead, multidisciplinary and accessible. It would have a strong research and education component. The current service was described as patchy, non-standardised, inconsistent and nihilistic. <h3>Conclusion</h3> Whilst British oncologists recognise bowel dysfunction after pelvic radiotherapy as a significant problem, they refer only a minority of patients for specialist evaluation. This may reflect the lack of clear routes of referral and access to GI expertise. The estimated proportion of patients affected was lower than that reported in the literature, which may reflect the lack of robust systems in routine practice to detect significant symptoms. The views expressed clearly highlight the need for a dedicated gastroenterology-lead multidisciplinary service to address the imbalance between this established unmet need and current service provision.
Authors’ Reply
Authors: Bryan T. Haddock, Henrik Larsson, Ulrik Andersen
Journal: Journal of the American Society of Nephrology (2019)

We thank Lifschitz1 for a valuable comment on our work. It is true that renal sympathetic nerve activity has not been directly measured in humans during isometric exercise, and therefore, the measured decrease in renal blood flow may in theory be caused by circulating vasoactive substances, such as adrenaline. However, it is well established that static exercise induces a generalized increase in muscle sympathetic nerve activity in humans,2 and an increase in renal sympathetic nervous activity has been directly measured in conscious cats in response to voluntary static exercise.3 In transplanted (denervated) kidneys in humans, only a small decrease in renal blood flow is seen in the late phase of fatiguing handgrip exercise as opposed to an early-onset, marked decrease in controls,4 suggesting that renal sympathetic nerves play the major role in the response. We, therefore, stand by our statement that the magnetic resonance techniques that we have described may be useful to evaluate the effect of renal denervation procedures. Disclosures None.
Marihuana: Buyer Beware
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diseases of the Rectum.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New York City's health care crisis: AIDS, the poor, and limited resources
Authors: A. Ron
Journal: JAMA (1988)

NEW YORK City is facing a major health care crisis—one that may be repeated in other American cities in the near future. This is the growing number of patients with acquired immunodeficiency syndrome (AIDS), whose care threatens to overwhelm the city's health care resources. In our city, minorities and the poor constitute an increasing proportion of new AIDS cases. In addition, the demographic makeup of this patient population creates an increasing potential for conflicts to erupt across racial and socioeconomic class lines. The majority of new AIDS diagnoses are in intravenous drug users, their sexual partners, and infants born to these couples. More than 80% of these patients are black or Hispanic<sup>1</sup>and almost all are poor. These groups, along with homosexual AIDS patients and substance abusers who don't have AIDS, are already placing great demands on limited hospital resources. It is becoming more difficult to arrange admission for